Study on a Vaccine Combined with Beta-glucan for People with Neuroblastoma

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06057948

Provider View

This clinical trial is testing different schedules of a vaccine combined with beta-glucan to find the most effective treatment for people with high-risk neuroblastoma who are in complete remission.

Patient Parameters

Program Overview

The aim of this study is to determine which schedule of administering a vaccine with beta-glucan works best for patients with high-risk neuroblastoma that is currently in complete remission. Neuroblastoma is a type of cancer that mostly affects children and can be very aggressive. This study focuses on patients who have already responded well to previous treatments and are in remission, meaning there are no signs of cancer at the moment.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with neuroblastoma based on specific medical criteria, such as lab tests or scans.
  • Classified as high-risk neuroblastoma, which includes certain aggressive forms of the disease.
  • Currently in complete remission, either after initial treatment or after further treatment for disease progression.
  • Have manageable side effects from previous treatments, as determined by medical tests.
    • Neutrophil count of at least 500/mcl.
    • Lymphocyte count of at least 500/mcl.
  • Between 21 and 180 days since finishing previous cancer treatment and starting the first vaccination.
  • Negative pregnancy test for those who can become pregnant.
  • Willing to sign a consent form acknowledging the experimental nature of the study.

Exclusion Criteria

  • Have severe side effects from previous treatments affecting blood, heart, nerves, lungs, kidneys, liver, or digestion.
  • Allergic to any components of the vaccine or beta-glucan.
  • Have received this vaccine before.
  • Have a serious infection that requires treatment.
  • Unable to follow the study requirements.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.